Mannose-binding lectin and the kidney.

et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. Magenheimer BS et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. Fujita H et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. slows disease progression in a rat model of polycystic kidney disease. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. A et al. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. A, Mulner O et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.